Symptoms of common mental disorders and adherence to antiretroviral therapy among adults living with HIV in rural Zimbabwe: a cross-sectional study. by Haas, Andreas D et al.
1Haas AD, et al. BMJ Open 2021;11:e049824. doi:10.1136/bmjopen-2021-049824
Open access 
Symptoms of common mental disorders 
and adherence to antiretroviral therapy 
among adults living with HIV in rural 
Zimbabwe: a cross- sectional study
Andreas D Haas   ,1 Cordelia Kunzekwenyika,2 Stefanie Hossmann,1 
Josphat Manzero,2 Janneke van Dijk,2 Ronald Manhibi,2 Ruth Verhey   ,3 
Andreas Limacher,4 Per M von Groote,1 Ethel Manda,3 Michael A Hobbins,5 
Dixon Chibanda,3,6,7 Matthias Egger   ,1,8,9 IeDEA Southern Africa
To cite: Haas AD, 
Kunzekwenyika C, Hossmann S, 
et al.  Symptoms of common 
mental disorders and adherence 
to antiretroviral therapy 
among adults living with HIV 
in rural Zimbabwe: a cross- 
sectional study. BMJ Open 
2021;11:e049824. doi:10.1136/
bmjopen-2021-049824
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2021- 
049824).
Received 03 February 2021
Accepted 18 June 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Andreas D Haas;  
 andreas. haas@ ispm. unibe. ch
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objectives To examine the proportion of people living 
with HIV who screen positive for common mental disorders 
(CMD) and the associations between CMD and self- 
reported adherence to antiretroviral therapy (ART).
Setting Sixteen government- funded health facilities in the 
rural Bikita district of Zimbabwe.
Design Cross- sectional study.
Participants HIV- positive non- pregnant adults, aged 18 
years or older, who lived in Bikita district and had received 
ART for at least 6 months.
Outcome measures The primary outcome was the 
proportion of participants screening positive for CMD 
defined as a Shona Symptoms Questionnaire score of 
9 or greater. Secondary outcomes were the proportion 
of participants reporting suicidal ideation, perceptual 
symptoms and suboptimal ART adherence and adjusted 
prevalence ratios (aPR) for factors associated with CMD, 
suicidal ideation, perceptual symptoms and suboptimal 
ART adherence.
Results Out of 3480 adults, 18.8% (95% CI 14.8% to 
23.7%) screened positive for CMD, 2.7% (95% CI 1.5% 
to 4.7%) reported suicidal ideations, and 1.5% (95% CI 
0.9% to 2.6%) reported perceptual symptoms. Positive 
CMD screens were more common in women (aPR 1.67, 
95% CI 1.19 to 2.35) than in men and were more common 
in adults aged 40–49 years (aPR 1.47, 95% CI 1.16 to 
1.85) or aged 50–59 years (aPR 1.51, 95% CI 1.05 to 2.17) 
than in those 60 years or older. Positive CMD screen was 
associated with suboptimal adherence (aPR 1.53; 95% CI 
1.37 to 1.70).
Conclusions A substantial proportion of people living 
with HIV in rural Zimbabwe are affected by CMD. There 
is a need to integrate mental health services and HIV 
programmes in rural Zimbabwe.
Trial registration number NCT03704805.
BACKGROUND
In 2019, approximately 1.4 million people 
were living with HIV in Zimbabwe, of whom 
more than 1.1 million were receiving antiret-
roviral therapy (ART).1 Widespread access to 
ART has dramatically improved the life expec-
tancy of people living with HIV.2 However, 
the long- term effectiveness of ART depends 
on lifelong retention in HIV care and strict 
medication adherence.3 4
Common mental disorders (CMD), which 
include depression and anxiety disorders are 
highly prevalent among people living with 
HIV. In sub- Saharan Africa, the estimated 
prevalence of major depression in people 
living with HIV is 15.3%, and of depressive 
symptoms 27.0%.5 The median prevalence of 
anxiety disorders in people living with HIV 
in low/middle- income countries is estimated 
at 22.8%.6 The prevalence of depression and 
anxiety disorders is higher in women than in 
men.7 8 In Zimbabwe’s capital Harare, over 
50% of people living with HIV attending a 
primary care facility met diagnostic criteria 
for either depression or anxiety, and 65% 
screened positive for CMD.9 10 In Zimbabwe, 
most people living with HIV receiving ART 
reside in rural areas,11 and the CMD preva-
lence in this population is unknown.
Strengths and limitations of this study
 ► Inclusion of a large sample of people living with 
HIV recruited at 16 government- funded primary 
and secondary care facilities in a rural district of 
Zimbabwe.
 ► Use of a locally developed screening tool that showed 
good psychometric properties for detecting common 
mental disorders in Zimbabwe in HIV- positive urban 
populations.
 ► The screening tool was not validated for the rural setting, 
and the cut- off score was selected based on data from 
the urban setting.
 ► Adherence to antiretroviral therapy was self- reported.
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The co- occurrence of mental disorders and HIV poses 
significant challenges in managing and treating HIV. 
Mental disorders are associated with poor HIV treatment 
outcomes, including low adherence, lack of viral load 
suppression, loss to follow- up and mortality.12–16 Early 
detection and effective management of mental disorders 
among people living with HIV may improve the quality 
of life of affected individuals, ART adherence and viral 
load suppression,17 18 thus reducing the incidence of HIV- 
associated complications, preventing drug resistance and 
HIV transmission. Despite these benefits, there is a large 
‘treatment gap’ in mental healthcare among people living 
with HIV in low- income and middle- income countries: 
most people affected by mental illness do not receive 
appropriate treatment.19 20
The Friendship Bench intervention is a culturally 
adapted evidence- based psychological intervention devel-
oped to close the treatment gap for CMD in Zimbabwe.21 
The Friendship Bench team trains community health 
workers to identify people with CMD symptoms and 
deliver a brief intervention consisting of six sessions of 
problem- solving therapy and optional group support.21 
We are conducting a cluster randomised trial to assess 
the effectiveness of the Friendship Bench intervention 
in improving ART outcomes and symptoms of CMD in 
people living with HIV in rural Zimbabwe. During recruit-
ment, we screened over 3500 ART patients for CMD and 
poor adherence. In this paper, we report the prevalence 
of positive CMD screening tests and associations between 
positive CMD screens and self- reported adherence among 
people living with HIV in rural Zimbabwe.
METHODS
We conducted a cross- sectional study at 16 health facili-
ties in Bikita district to assess the eligibility of individuals 
for a cluster randomised trial (FB- ART) on the effect of 
the Friendship Bench intervention22 on ART outcomes 
and symptoms of CMD in people living with HIV. Bikita 
is a rural district of the Masvingo Province about 300 km 
south of Harare.
Between 5 October 2018 and 19 December 2019, we 
offered CMD screening at 16 government- funded health 
facilities in rural Zimbabwe. HIV- positive non- pregnant 
adults aged 18 years or older who lived in Bikita district 
and had received ART for at least 6 months were eligible. 
Trained research assistants offered screening for CMD 
using the Shona Symptoms Questionnaire (SSQ-14)9 and 
assessed adherence using a question from the AIDS indi-
cator survey.23 The SSQ-14 is a locally developed CMD 
screening tool.9 The tool assesses if individuals had expe-
rienced common mental health symptoms, including 
sleep disturbance, suicidal ideations, tearfulness, percep-
tual symptoms and impairment of functioning in the 
past 7 days. Each of the 14 symptoms is scored dichoto-
mously (symptom present or absent).24 The tool showed 
good psychometric properties for detecting CMD in 
HIV- positive and HIV- negative urban populations in 
Zimbabwe.9 An SSQ-14 score of ≥9 had a sensitivity of 
88% and a specificity of 76% for depression or general 
anxiety in HIV- positive adults in Harare.9 The tool had a 
high internal consistency in the validation study (Cron-
bach’s α=0.74) and in our study (Cronbach’s α=0.82). 
Adherence was assessed based on self- report using the 
following question: ‘In the last 30 days, how many days 
have you missed taking any of your ARV [antiretroviral] 
pills?’.23
We defined SSQ-14 scores of 9 or greater as positive 
CMD screen.9 Participants who reported that they ‘felt 
like committing suicide’ in the past 7 days (SSQ-14 item 
11) screened positive for suicidal ideation. Participants 
who reported that they ‘saw or heard things which others 
could not see or hear’ in the past 7 days (SSQ-14 item 5) 
screened positive for perceptual symptoms. Participants 
who indicated that they had missed taking one or more 
ARV pills in the last 30 days were classified as having 
suboptimal adherence. Those reporting not having 
missed any ARV pills had optimal adherence. We catego-
rised age into the following groups: 18–29 years, 30–39 
years, 40–49 years, 50–59 years and 60 years or older.
Individuals who participated in SSQ screening were 
eligible for this analysis. Participants who did not respond 
to all 14 SSQ items were excluded. We calculated the 
prevalence of non- adherence and positive screening 
outcomes with logit- transformed 95% CIs that adjusted 
for intragroup correlation at health facilities. We esti-
mated adjusted prevalence ratios (aPRs) for factors asso-
ciated with positive screening for CMD, suicidal ideation 
and perceptual symptoms using mixed- effects Poisson 
regression models with robust standard errors.25 Models 
were adjusted for sex, age and clustering of data at facility- 
level using a random intercept for study facilities. We 
used the same models to calculate unadjusted and aPRs 
for factors associated with suboptimal adherence. Statis-
tical analysis was done using Stata (V.16, Stata).
Individuals who screened positive for CMD and 
provided written informed consent were included in 
the trial and were offered CMD treatment as part of the 
FB- ART (friendship bench- antiretroviral therapy) trial.
Patient and public involvement
Patients with psychiatric morbidity were involved in 
ethnographic and qualitative research, which informed 
the development of the SSQ-14.24 The results of this study 
were shared with the provincial medical director and the 
district medical officer.
RESULTS
Research assistants assessed the eligibility for CMD 
screening of 3707 individuals: 3543 (95.6%) of eligible 
individuals participated in CMD screens. Pregnancy, 
residency outside of Bikita district and age below 18 
years were the most common reasons for ineligibility for 
screening. Out of 3543 individuals screened for CMD, 
63 (1.7%) did not respond to all SSQ-14 items and were 
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excluded. The remaining 3480 individuals were included 
in the analysis. The median age of the study population 
was 45 years (IQR 38–53). Three- quarters of the partici-
pants (74.9%, n=2608) were women.
Table 1 shows the prevalence and aPRs for positive 
screening for CMD, suicidal ideation and perceptual 
symptoms. Out of 3480 adults, 18.8% (95% CI 14.8% to 
23.7%, n=655) screened positive for CMD, 2.7% (95% 
CI 1.5% to 4.7%, n=93) reported suicidal ideation, and 
1.5% (95% CI 0.9% to 2.6%, n=52) reported perceptual 
symptoms. Positive CMD screens were more common in 
women (21.0%; aPR 1.67, 95% CI 1.19 to 2.35) than in 
men (12.4%) and were more common in adults aged 
40–49 years (20.6%; aPR 1.47 95% CI 1.16 to 1.85) or aged 
50–59 years (20.3%; aPR 1.51 95% CI 1.05 to 2.17) than in 
those 60 years or older (12.6%). Suicidal ideations were 
more common in adults 18–29 years (4.7%, 95% CI 0.2% 
to 9.2%) and in adults aged 30–39 years (4.0%, 95% CI 
1.1% to 7.0%) than in older adults, but the statistical 
uncertainty around these estimates was large.
Out of 3469 individuals who responded to the adher-
ence question (11, 0.32% did not respond), 2900 (83.6%, 
95% CI 80.0% to 87.2%) reported optimal adherence and 
569 (16.4%, 95% CI 12.8% to 20.0%) reported suboptimal 
adherence. Suboptimal adherence was more common in 
individuals screening positive for CMD (aPR 1.53, 95% CI 
1.37 to 1.70) than in those screening negative (table 2). 
Suboptimal adherence was also more common in men 
(aPR 1.25, 95% CI 1.01 to 1.53) than in women and adults 
aged 18–29 years (aPR 1.62, 95% CI 1.10 to 2.38) than in 
those 60 years or older (table 2).
DISCUSSION
In a rural district of Zimbabwe, about one in five HIV 
positive adult screened positive for CMD, almost 3% 
reported suicidal ideation, and 1.5% perceptual symp-
toms compatible with psychosis. Positive CMD screens 
were more common in women and middle- aged adults 
than in men or older adults. Positive CMD screens were 
associated with suboptimal self- reported ART adherence.
Our results have to be considered in light of two limita-
tions. First, we used a locally developed CMD screening 
tool that had been validated in urban Zimbabwe, but we 
did not validate the tool for the rural setting and selected 
the CMD threshold based on the urban validation study.9 
Second, we used a self- reported adherence measure which 
might be prone to under- reporting of non- adherence. 
However, there is evidence for the validity of self- reported 
measures of ART adherence.26 The strengths of our study 
include a large sample size and a multicentre design.
In line with the national10 and international litera-
ture,27 28 we found that CMDs were much more common 
in women than in men. Biological factors, including sex 
hormones and sex differences in the neuroendocrine 
response to stress, psychosocial factors such as gender 
differences in interpersonal orientation, self- esteem, 
body shaming and rumination might contribute to the 
gender gap in CMD.7 8 In addition to these individual- level 
factors, gender inequity and higher exposure of women 
and girls to traumatising life events, including gender- 
based violence or sexual abuse, may further contribute to 
the gender gap in CMD.7 10 29
The prevalence of positive CMD screens observed 
in our study of a rural HIV positive population was less 
than one- third of the prevalence observed in a study 
of a similar urban population conducted in Harare in 
2013.9 10 An important factor that likely contributed to 
the lower prevalence of CMD in our study compared with 
earlier studies is the change of national ART guidelines 
to treat people living with HIV at less advanced stages of 
HIV disease. In the last decade, the CD4 threshold for 
ART eligibility was successively raised from <250 cells/
µL to immediate ART initiation of all people living with 
HIV under WHO’s ‘treat all’ guidelines. These changes 
were reflected in an increase in the median CD4 at ART 
initiation in low and middle income.30 31 Low CD4 cell 
count is associated with a higher risk of CMD,32 and the 
comparably low prevalence of CMD observed in our 
study might reflect the higher median CD4 cell count 
at ART initiation. The gap in CMD prevalence between 
the urban and the rural setting might also be explained 
by a high prevalence of adverse living condition in the 
urban areas: 42% of the HIV positive individuals included 
in the urban study were unemployed, and 92% reported 
that they experienced a negative life event (eg, death 
in the family, physical or sexual assault, forced eviction, 
HIV diagnosis or hospitalisation of the participant or an 
immediate family member) in the 6 months before data 
collection.9 10 Furthermore, cultural differences in symp-
toms presentation between urban and rural populations 
might explain differences in the prevalence between the 
two settings.33
Our results confirm earlier data on associations 
between symptoms of depression and anxiety disorders 
and suboptimal adherence to ART.12 15 A meta- analysis 
of eight studies from low- income countries found that 
the odds of suboptimal adherence were 92% higher in 
patients with depressive symptoms than those without 
depressive symptoms (OR 1.92, 95% CI 1.47 to 2.5).15 
Another meta- analysis of 11 studies from low- income and 
middle- income countries showed that anxiety disorders 
were associated with a substantial increase in the odds of 
suboptimal adherence (OR 1.59, 95% CI 1.29 to 1.96).12 
The strength of the association observed in our study was 
consistent with these meta- analyses.
Our findings show a substantial burden of CMD among 
people living with HIV in rural Zimbabwe and under-
line the need to integrate interventions for detecting 
and addressing CMD in this population. The Friendship 
Bench project is an evidence- based psychological inter-
vention for delivering mental healthcare in primary 
care.21 The intervention has been rigorously evaluated 
in a large cluster randomised controlled trial in Harare, 
which showed that the Friendship Bench intervention 
substantially improved CMD symptoms.21 As part of the 
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FB- ART trial, we have implemented the FB intervention 
at the eight intervention sites participating in the FB- ART 
trial, and will further roll out to the eight control sites to 
provide access to evidence- based mental health services 
for people attending these clinics.
Treatment of mental disorders among people living 
with HIV may also positively affect HIV treatment 
outcomes.17 18 A meta- analysis of 29 observational studies 
and randomised trials showed that depression and psycho-
logical distress treatment enhances ART adherence.18 
A further meta- analysis of three randomised controlled 
trials provides weak evidence for the benefit of cogni-
tive behavioural therapy for depression and adherence 
on viral load suppression.17 34–36 Despite these promising 
results, the evidence for the benefit of mental healthcare 
for improving HIV treatment outcomes is still limited.
Further work is needed to evaluate the effect of mental 
healthcare on the mental health of people living with 
HIV and HIV treatment outcomes. We are currently eval-
uating the effect of the Friendship Bench intervention on 
ART adherence, viral load suppression and symptoms of 
CMD among people living with HIV in rural Zimbabwe. 
There is also a need for continued routine programme 
monitoring and implementation science to ensure the 
quality and effectiveness of the Friendship Bench inter-
vention in various settings.
In conclusion, our findings show a substantial burden 
of CMD among people living with HIV in rural Zimbabwe 
and underline the need to integrate mental health 
services in HIV treatment programmes.
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Table 2 Prevalence ratios for factors associated with 









  Negative‡ 1.00 1.00
  Positive§ 1.46 (1.29 to 1.66) 1.53 (1.37 to 1.70)
Sex
  Female 1.00 1.00
  Male 1.17 (0.96 to 1.44) 1.25 (1.01 to 1.53)
Age in years
  18–29 1.60 (1.10 to 2.31) 1.62 (1.10 to 2.38)
  30–39 1.29 (0.90 to 1.85) 1.31 (0.91 to 1.89)
  40–49 1.00 (0.72 to 1.38) 0.99 (0.71 to 1.38)
  50–59 1.04 (0.72 to 1.51) 1.03 (0.71 to 1.49)
  60+ 1.00 1.00
Data are unadjusted and adjusted prevalence ratios. 95% CIs are 
shown in parenthesis.
*Models adjusted for clustering of participants in facilities.
†Models adjusted for CMD screening, sex, age and clustering of 
participants in facilities.
‡SSQ-14 scores of smaller than 9.
§SSQ-14 scores of 9 or greater.
CMD, common mental disorders ; SSQ-14, Shona Symptoms 
Questionnaire.
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